{"aliases":[{"type":"Synonym","name":"rituximab-arrx"},{"type":"Synonym","name":"rituximab biosimilar BI 695500"},{"type":"CodeName","name":"ABP 798"},{"type":"CodeName","name":"IDEC-C2B8"},{"type":"CodeName","name":"IDEC-102"},{"type":"CodeName","name":"CT-P10"},{"type":"Synonym","name":"rituximab biosimilar SIBP-02"},{"type":"Synonym","name":"rituximab ARRX"},{"type":"Synonym","name":"rituximab-pvvr"},{"type":"Synonym","name":"chimeric anti-CD20 antibody"},{"type":"Synonym","name":"IDEC-C2B8 monoclonal antibody"},{"type":"Synonym","name":"rituximab biosimilar SAIT101"},{"type":"Synonym","name":"C2B8 monoclonal antibody"},{"type":"Synonym","name":"rituximab PVVR"},{"type":"USBrandName","name":"Truxima"},{"type":"Synonym","name":"rituximab biosimilar RTXM83"},{"type":"USBrandName","name":"Ruxience"},{"type":"CodeName","name":"RTXM83"},{"type":"Synonym","name":"rituximab biosimilar PF-05280586"},{"type":"Synonym","name":"monoclonal antibody IDEC-C2B8"},{"type":"USBrandName","name":"Rituxan"},{"type":"CodeName","name":"BI 695500"},{"type":"USBrandName","name":"Riabni"},{"type":"CodeName","name":"rituximab biosimilar JHL1101"},{"type":"CodeName","name":"PF-05280586"},{"type":"Synonym","name":"rituximab biosimilar IBI301"},{"type":"Synonym","name":"rituximab biosimilar TQB2303"},{"type":"Synonym","name":"rituximab ABBS"},{"type":"Synonym","name":"rituximab biosimilar ABP 798"},{"type":"ForeignBrandName","name":"MabThera"},{"type":"Synonym","name":"rituximab biosimilar GB241"},{"type":"Synonym","name":"rituximab biosimilar CT-P10"},{"type":"Synonym","name":"rituximab-abbs"},{"type":"CASRegistryName","name":"174722-31-7"},{"type":"ForeignBrandName","name":"Ikgdar"},{"type":"ForeignBrandName","name":"Mabtas"}],"definition":{"html":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.","text":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/rituximab","text":"Rituximab"},"nciConceptId":"C1702","nciConceptName":"Rituximab","termId":42613,"name":"rituximab","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"rituximab"}